Active targeting of tumor treatment

By | December 8, 2011

In recent years, active targeting of tumor treatment a lot of progress, due to the development of biotechnology, there are a variety of biological molecules have been used in clinical or ongoing clinical studies.
1. Active antibody-mediated tumor targeted therapy of antibody and antibody fragment as a cancer diagnosis and treatment of a new wave of wave into the clinic, "engineered antibody" will be the first time the term accepted by the public. Such as the FDA approved recombinant antibodies effective for cancer treatment, including "Rituxam" CIDEC and "Bexxar" two roles in CD2. Treatment of non-Hodgkin's lymphoma, "Herceptin" treatment of breast cancer. These antibodies to treat cancer potential market value in 2001 will exceed 10 billion U.S. dollars. Antibody and antibody fragment-mediated tumor targeted therapy with the first major initiative for many of the blood system cancer tumor to his current treatment. Because anti-tumor angiogenesis in-depth, sat for tumor angiogenesis because of its broad spectrum of antibodies which have broad application prospects, there are already more than ten kinds of clinical research into III.
2. Other biological molecules mediated tumor therapy in addition to active targeting antibodies and antibody fragments in cancer targeted therapy, the effect on tumor growth and division and other biological molecules of different aspects of the development of targeted agents is greater. ZD1839 is an oral selective epidermal growth factor receptor tyrosine kinase inhibitors, Japan conducted the first Phase I clinical trial, 20% of non-small cell lung cancer patients showed remission confirmed, and the preparation of patients well tolerated.
3. Premise of drug-mediated tumor targeted therapy using the premise of active drugs into the rank of targeted cancer therapy is able to reduce the side effects of chemotherapy drugs to enhance anti-tumor activity, so by the chemotherapy industry attention.
In recent years, fluoride slightly rotating categories: drug development and clinical application have made great progress, and its clever design and a unique activation mechanism succeeded in increasing anti-tumor specificity. There are currently used in clinical fluoride Citroen and Xeloda. F Citroen (deoxy-fluorouracil past ,5-DFUR) is a 5-FU precursors, fluorine Citroen is shown by the high activity in tumor tissue is slightly crisp nuclear past phosphorylase (PyNPase) into 5-FU and, therefore, has a selective fluoride Citroen anti-tumor effects. Citroen fluoride in the treatment of gastric cancer, colorectal cancer, breast cancer , cervical cancer, bladder cancer, nasopharyngeal carcinoma and other tumors can replace 5-FU, has greatly improved efficiency, mild adverse reactions. Xeloda (capecitabine, capecitabine, xeloda) 1998 5 The first thing in the U.S.. The activation is subject to three steps: Step 1 by the carboxylic acids in the liver enzyme (carboxylesterase) to Xeloda transformed into an oxygen -5– little fluoride cell nuclear Cao Institute (5DFCR), then in the liver or tumor tissue slightly from the cell knows deaminase (cytidine deaminase) to 5-DFCR into 5-DFUR, Step 3 by the PyNPas role in tumor tissues selectively. Study further confirmed that, PyNPase activity in tumor tissue than the adjacent normal tissues from 3 to 10 times. Currently, capecitabine is an effective drug in the treatment of metastatic breast cancer; In addition, oral Xeloda in advanced colorectal cancer when comparing the efficiency of clinical studies have shown that there is significantly higher.

Leave a Reply

Your email address will not be published. Required fields are marked *